Santersus AG
Zurich, Zurich, Switzerland · Biotechnology, Health Care, Medical
Zurich-based Santersus AG is a biotechnology company developing NucleoCapture, a novel, patent-protected extracorporeal blood purification technology designed to selectively remove cell-free DNA (cfDNA) and neutrophil extracellular traps (NETs). The company is focused on advancing NucleoCapture for various critical medical needs including sepsis, systemic lupus erythematosus, solid-organ transplan
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Zurich, Zurich, Switzerland
- Employees
- 7
- Industries
- Biotechnology, Health Care, Medical
- Website
- santersus.com
- Company page
Recent activity at Santersus AG
About Santersus AG: questions and answers
What does Santersus AG do?
Zurich-based Santersus AG is a biotechnology company developing NucleoCapture, a novel, patent-protected extracorporeal blood purification technology designed to selectively remove cell-free DNA (cfDNA) and neutrophil extracellular traps (NETs). The company is focused on advancing NucleoCapture for various critical medical needs including sepsis, systemic lupus erythematosus, solid-organ transplan
Where is Santersus AG headquartered?
Santersus AG is headquartered in Zurich, Zurich, Switzerland.
How many employees does Santersus AG have?
Santersus AG has about 7 employees.
What is the latest news on Santersus AG?
On Dec 01, 2025, Santersus AG raises Series A funding led by Norcliffe, with participation from Terumo Ventures to advance NucleoCapture for sepsis treatment.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy